Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Adding sexual-pleasure conversations to harm reduction services for MSM and transgender people who do chemsex in Thailand

Official title: Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engage in Chemsex or Substance Use in Thailand

Run by Institute of HIV Research and Innovation Foundation, Thailand · NCT07509853 · Data updated 2026-11-12

This project will try using a 'Pleasuremeter' to guide sexual-pleasure conversations in harm reduction services for MSM and transgender people who engage in chemsex or substance use in Thailand to see if it improves sexual health, substance use, and related outcomes.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorInstitute of HIV Research and Innovation Foundation, Thailand
Academic / other
Locations1 site (Pathum Wan, Bangkok)
StatusRecruiting
StartedMay 1, 2025
Main results expectedMay 1, 2027
Study endsMay 1, 2028
Registry record updatedApril 8, 2026
Trial IDNCT07509853 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) in Thailand who are men who have sex with men, transgender women or men, or non-binary people who have engaged in chemsex or substance use in the past 12 months and can provide informed consent in Thai.

Probably not a fit

People who cannot communicate in Thai, are younger than 18, or have not engaged in chemsex or recent substance use are unlikely to benefit from this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a sequential exploratory mixed-methods implementation project at the Institute of HIV Research and Innovation clinics in Bangkok. The work begins with qualitative interviews to adapt the 'Pleasuremeter' tool and then integrates the tool into harm reduction service encounters. About 300 participants will be enrolled and followed at baseline, month 3, and month 6 to track sexual pleasure, behavioral risk, substance use, HIV/STI testing, mental health, and socio-legal factors. The study also measures acceptability, satisfaction, and feasibility of using a pleasure-based approach in existing services.

Why it matters

Potential benefit: If successful, this approach could improve engagement with harm reduction services, increase HIV/STI testing and safer behaviors, and better address sexual wellbeing for MSM and transgender people who do chemsex.

How similar studies have gone: Pleasure-focused sexual-health approaches are relatively novel; while some behavioral harm-reduction programs for people who use drugs have shown benefits, integrating a 'Pleasuremeter' into clinical services in this population and setting is largely untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* MSM, transgender women, transgender men, or non-binary persons
* Age ≥18 years
* Engaged in chemsex or substance use within past 12 months
* Able to provide informed consent

Exclusion Criteria:

• Unable to communicate in Thai sufficiently to complete study procedures

Where it's running

  • Tangerine Clinic, Institute of HIV Research and Innovation
    Pathum Wan, Bangkok, Thailand
    Recruiting

Study contacts

  • Principal investigator: Akarin Hiransuthikul, MD,MSc — Chulalongkorn University
  • Study coordinator: Nittaya Phanuphak, MD,PhD.
  • Email: nittaya.p@ihri.org
  • Phone: 6681 825 3544

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.